AstraZeneca Says Durvalumab May Be Off The US Fast Track In NSCLC
This article was originally published in Scrip
Executive Summary
Advances by competing medicines in the field of lung cancer mean AstraZeneca PLC's PD-L1 inhibitor durvalumab (MEDI4736) may not get to market as quickly as first hoped, the company said Nov. 5 when presenting its third quarter results.